<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327546</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0012</org_study_id>
    <nct_id>NCT02327546</nct_id>
  </id_info>
  <brief_title>Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548</brief_title>
  <official_title>An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the single-dose bioavailability of AKB-6548
      with ferrous sulfate relative to AKB-6548 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of AKB-6548: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of AKB-6548: Area under the curve from time 0 until the last quantifiable concentration (AUC [last])</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of AKB-6548: Area under the concentration-time curve from 0 to infinity (AUCinf)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548: Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548: Terminal elimination rate constant (λz)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548: Plasma half life (t1/2)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548: Apparent total systemic clearance (CL/F)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548: Apparent volume of distribution during the terminal elimination phase (VzF)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548 metabolites: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548 metabolites: Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548 metabolites: Terminal elimination rate constant (λz)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548 metabolites: Plasma half life (t1/2)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548 metabolites: Area under the curve from time 0 until the last quantifiable concentration (AUC [last])</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AKB-6548 metabolites: Area under the concentration-time curve from 0 to infinity (AUCinf)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite to parent drug for maximum plasma concentration (Cmax)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite to parent drug for are under the curve from time 0 until the last quantifiable concentration (AUC [last])</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite to parent drug for area under the concentration-time curve (AUC)</measure>
    <time_frame>Multiple timepoint evaluations from pre-dose to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AKB-6548</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AKB-6548</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKB-6548 plus Ferrous Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AKB-6548 plus ferrous sulfate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKB-6548</intervention_name>
    <arm_group_label>AKB-6548</arm_group_label>
    <arm_group_label>AKB-6548 plus Ferrous Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <arm_group_label>AKB-6548 plus Ferrous Sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects 18 to 55 years of age with a body mass index between 18 and 30
             kg/m2

          -  Participants and their partners must use a highly effective form of contraception
             during the study and for 1 month following discharge from the Clinical Research Unit
             (CRU)

          -  Subjects must discontinue all iron preparations for 14 days prior to study drug
             administration

        Exclusion Criteria:

          -  Current or past history of cardiovascular, cerebrovascular, pulmonary, renal or liver
             disease

          -  Positive serology results for HBsAg, HCV, and HIV at Screening

          -  Renal impairment (estimated glomerular filtration rate (eGFR) of &lt;65mL/min)

          -  Known active cancer (except non-melanoma skin cancer) or history of chemotherapy use
             within the previous 24 months

          -  Current or past history of gastric or duodenal ulcers or other diseases of the GI
             tract (including gastric bypass surgeries) that could interfere with absorption of
             study drug

          -  Subjects with a known history of smoking and/or have used nicotine or
             nicotine-containing products within the past 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akshay Buch</last_name>
    <role>Study Chair</role>
    <affiliation>Akebia Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Anemia</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>Chronic renal insufficiency</keyword>
  <keyword>Renal impairment</keyword>
  <keyword>Ferrous sulfate</keyword>
  <keyword>Iron</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Oral anemia treatment</keyword>
  <keyword>Hypoxia-induciable factor</keyword>
  <keyword>HIF</keyword>
  <keyword>Hypoxia-induciable factor prolyl-hydroxylase inhibitor</keyword>
  <keyword>HIF-PHI</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

